ViTToria Biotherapeutics, co-founded by Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Penn Medicine, has secured $25 million in private financing to advance its phase 1 clinical trial for VIPER-101. This funding is a $10 million extension to its previous $15 million financing secured in November 2023.
VIPER-101, a T cell therapy targeting T-cell lymphoma, utilizes the proprietary Senza5TM platform, which enhances T cell efficacy through gene editing and features a rapid five-day manufacturing process. Senza5 has demonstrated outstanding preclinical anti-tumor efficacy across a range of liquid and solid tumor models and enhanced production efficiency. ViTToria’s VIPER-101 clinical trial is actively recruiting patients and information about the trial can be found here. Read more about ViTToria here and here.